Research Articles Library
Literature Analysis Tools
Advanced Search
Filter by PMID, year, source, DOI and other criteria
Literature Analysis
Analyze research trends and hotspots
Batch Export
Export search results to Excel/PDF
[Erratum to: New treatment targets for inflammatory bowel disease?]
Publication Year: 2025 Source: Inn Med (Heidelb) PMID: 40009176
No Abstract
Genetic Variants and Clinical Features of Patients With Glycogen Storage Disease Type Ib
Publication Year: 2025 Source: JAMA Netw Open PMID: 40009380 DOI: 10.1001/jamanetworkopen.2024.61888
IMPORTANCE: Glycogen storage disease type Ib (GSDIb) is a rare metabolic disorder characterized by impaired glucose-6-phosphate transporter function with limited descriptions. OBJECTIVE: To describe the genetic and clinical features of Chinese patients with GSDIb. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study retrieved the medical records of 113 Chinese patients …
The Relationship Between Intramural Fat Accumulation and Sarcopenia on MR Enterography Exams in Patients with Crohn's Disease
Publication Year: 2025 Source: Rofo PMID: 38977011
No Abstract
How Artificial Intelligence Will Transform Clinical Care, Research, and Trials for Inflammatory Bowel Disease
Publication Year: 2025 Source: Clin Gastroenterol Hepatol PMID: 38992406 DOI: 10.1016/j.cgh.2024.05.048
Artificial intelligence (AI) refers to computer-based methodologies that use data to teach a computer to solve pre-defined tasks; these methods can be applied to identify patterns in large multi-modal data sources. AI applications in inflammatory bowel disease (IBD) includes predicting response to therapy, disease activity scoring of endoscopy, drug discovery, …
Diet and Microbiome-Directed Therapy 2.0 for IBD
Publication Year: 2025 Source: Clin Gastroenterol Hepatol PMID: 38992408 DOI: 10.1016/j.cgh.2024.05.049
Inflammatory bowel disease (IBD) comprises chronic and relapsing disorders of the gastrointestinal tract, characterized by dysregulated immune responses to the gut microbiome. The gut microbiome and diet are key environmental factors that influence the onset and progression of IBD and can be leveraged for treatment. In this review, we summarize …
Prediction and Prevention of Inflammatory Bowel Disease
Publication Year: 2025 Source: Clin Gastroenterol Hepatol PMID: 38996831
No Abstract
Metformin Is Associated With Improved Inflammatory Bowel Disease Outcomes in Patients With Type 2 Diabetes Mellitus: A Propensity-Matched Cohort Study
Publication Year: 2025 Source: Inflamm Bowel Dis PMID: 39001616 DOI: 10.1093/ibd/izae147
BACKGROUND: Metformin exerts anti-inflammatory properties through a positive effect on oxidative stress, gut barrier integrity, and the gut microbiota. Our aim was to evaluate the influence of metformin on inflammatory bowel disease (IBD) outcomes in patients with type 2 diabetes mellitus (T2DM). METHODS: We conducted a retrospective cohort study using …
Postbiotics in inflammatory bowel disease: efficacy, mechanism, and therapeutic implications
Publication Year: 2025 Source: J Sci Food Agric PMID: 39007163 DOI: 10.1002/jsfa.13721
Inflammatory bowel disease (IBD) is one of the most challenging diseases in the 21st century, and more than 10 million people around the world suffer from IBD. Because of the limitations and adverse effects associated with conventional IBD therapies, there has been increased scientific interest in microbial-derived biomolecules, known as …
Dress me an outfit: advanced probiotics hybrid systems for intelligent IBD therapy
Publication Year: 2025 Source: Crit Rev Food Sci Nutr PMID: 39007752 DOI: 10.1080/10408398.2024.2359135
Inflammation bowel disease (IBD) has emerged as a public health challenge worldwide; with high incidence and rapid prevalence, it has troubled billions of people and further induced multitudinous systemic complications. Recent decade has witnessed the vigorous application of food-borne probiotics for IBD therapy; however, the complicated and changeable environments of …
When Perfect Is the Enemy of Good: Results of a RAND Appropriateness Panel on Treat to Target in Asymptomatic Inflammatory Bowel Disease
Publication Year: 2025 Source: Am J Gastroenterol PMID: 39008539 DOI: 10.14309/ajg.0000000000002964
BACKGROUND: A treat-to-target strategy for inflammatory bowel disease (IBD) recommends iterative treatment adjustments to achieve clinical and endoscopic remission. In asymptomatic patients with ongoing endoscopic activity, the risk/benefit balance of this approach is unclear, particularly with prior exposure to advanced therapies. METHODS: Using the RAND/University of California Los Angeles Appropriateness …
Need more literature?
The current database contains 98453 research articles. If you need to search for more literature or perform AI analysis, please use our knowledge acquisition module or explore external literature resources.
External Resources: Access comprehensive literature databases worldwide